ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1469

Manhattan Study: Observational, Ambispective Study to Describe Persistence and Effectiveness of a Second-line Guselkumab or TNF Inhibitors After First-line TNF Inhibitors for the Treatment of Active Psoriatic Arthritis in Spain
Abstract Number: 1844

Manufacturing of IMPT-514, a CD19/CD20 Bispecific CAR T Cell Product Candidate as a Potential Treatment of Patients with Autoimmune Diseases
Abstract Number: 1558

Mapping in Healthy Subjects Different Body Areas for Dermal Thickness and Skin Hardness by High Frequency Sonography and Durometry
Abstract Number: 1091

Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study
Abstract Number: 0361

Maternal and Fetal Outcomes in Those with Autoimmune Connective Tissue Disease
Abstract Number: 1322

Maternal Antenatal Attachment in Women with Rheumatic Diseases
Abstract Number: 2233

Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis
Abstract Number: 0307

Mean Metacarpophalangeal Extension to Clinically Quantify Flexor Fibro-inflammatory Hand Involvement in Diabetes
Abstract Number: 0342

Measurement of Serum Cytokine and Chemokine Level to Predict Poor Treatment Response in Patients with Idiopathic Inflammatory Myositis
Abstract Number: 0541

Measurement Properties of Disease Activity Instruments in Peripheral Spondyloarthritis. an Analysis in the CRESPA Trial
Abstract Number: 2624

Measuring Clinically Inactive Disease at One Year in Patients with Juvenile Dermatomyositis (JDM) in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Abstract Number: 1308

Measuring the Educational Impact of a Collaboration Between RheumMadness and TheMednet
Abstract Number: 0973

Mechano-transduction via MRTF-A Pathway Is Required for Cytokine Release by Scleroderma Macrophages
Abstract Number: 1230

Mediating Role of Pain Catastrophizing in Racial Disparities in Knee Osteoarthritis Pain Among Non-Hispanic White and Asian Americans: A Pilot Study
Abstract Number: 1217

Medical and Non-Medical Cannabis Use by Rheumatology Patients: A Study of over 2000 Patients in California

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].